Compare PDX & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDX | PSNL |
|---|---|---|
| Founded | 2019 | 2011 |
| Country | NY | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 904.4M | 729.1M |
| IPO Year | N/A | 2019 |
| Metric | PDX | PSNL |
|---|---|---|
| Price | $20.07 | $8.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 113.8K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | ★ 4.95% | N/A |
| EPS Growth | N/A | ★ 33.58 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $69,648,000.00 |
| Revenue This Year | N/A | $19.49 |
| Revenue Next Year | N/A | $30.84 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.47 | $2.83 |
| 52 Week High | $25.61 | $11.50 |
| Indicator | PDX | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 51.13 | 50.12 |
| Support Level | $19.91 | $7.28 |
| Resistance Level | $20.36 | $9.67 |
| Average True Range (ATR) | 0.19 | 0.70 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 49.06 | 56.94 |
PIMCO Dynamic Income Strategy Fund is a non-diversified, limited-term, closed-end management investment company. It seeks current income as a primary objective and capital appreciation as a secondary objective. The fund makes investments using a dynamic asset allocation plan among multiple sectors in the public and private credit markets globally, including corporate debt, mortgage-related and other asset-backed instruments, government and sovereign debt, taxable municipal bonds, and other fixed, variable, and floating-rate income-producing securities of U.S. and foreign issuers, including emerging market issuers and real estate-related investments.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.